Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins
Strong Q3 Earnings Propel Stock Higher Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecast investing.com. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly $0.79 loss expected. Management immediately lifted the full-year sales outlook to $965–970 million (about 31% growth) investors.guardanthealth.com, up from $915–925M previously. As a result, GH stock jumped nearly 30% in morning trading on Oct. 30 (to about $94, from ~$72
